Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up – What’s Next?

Fresenius SE & Co. (OTCMKTS:FSNUY) shares gapped up before the market opened on Wednesday. The stock had previously closed at $12.56, but opened at $13.36. Fresenius SE & Co. shares last traded at $12.9075, with a volume of 13,854 shares trading hands.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on FSNUY shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Fresenius SE & Co. Trading Up 2.2%

The firm has a fifty day moving average of $12.98 and a 200-day moving average of $12.35. The stock has a market capitalization of $28.93 billion, a price-to-earnings ratio of 16.25 and a beta of 0.60. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28.

Fresenius SE & Co. (OTCMKTS:FSNUY) last posted its earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $6.91 billion during the quarter, compared to analyst estimates of $6.65 billion. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. As a group, equities analysts predict that Fresenius SE & Co. will post 1.08 earnings per share for the current fiscal year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.